Proficio Capital Partners LLC Invests $358,000 in Envista Holdings Co. (NYSE:NVST)

Proficio Capital Partners LLC bought a new stake in Envista Holdings Co. (NYSE:NVST - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 18,576 shares of the company's stock, valued at approximately $358,000.

Other institutional investors have also recently bought and sold shares of the company. Pacer Advisors Inc. grew its holdings in Envista by 22.2% in the third quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company's stock valued at $69,749,000 after purchasing an additional 642,401 shares during the period. Diamond Hill Capital Management Inc. grew its holdings in Envista by 8.1% in the third quarter. Diamond Hill Capital Management Inc. now owns 1,335,710 shares of the company's stock valued at $26,394,000 after purchasing an additional 100,360 shares during the period. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Envista in the fourth quarter valued at approximately $53,000. Lecap Asset Management Ltd. purchased a new stake in Envista in the fourth quarter valued at approximately $281,000. Finally, Hotchkis & Wiley Capital Management LLC purchased a new stake in Envista during the third quarter worth approximately $14,965,000.

Wall Street Analyst Weigh In

Several research firms have issued reports on NVST. JPMorgan Chase & Co. decreased their price objective on shares of Envista from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Mizuho began coverage on shares of Envista in a research note on Wednesday, December 4th. They set an "underperform" rating and a $20.00 price objective for the company. Piper Sandler boosted their price objective on shares of Envista from $17.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Wells Fargo & Company set a $19.00 price objective on shares of Envista in a research note on Saturday, March 8th. Finally, Morgan Stanley decreased their price objective on shares of Envista from $20.00 to $19.00 and set an "equal weight" rating for the company in a research note on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Envista presently has an average rating of "Hold" and a consensus price target of $20.18.

Remove Ads

Envista Stock Performance

Shares of Envista stock traded up $0.38 during trading hours on Friday, reaching $16.63. The company's stock had a trading volume of 3,077,798 shares, compared to its average volume of 2,381,075. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. Envista Holdings Co. has a one year low of $15.15 and a one year high of $23.00. The company's 50 day simple moving average is $20.04 and its 200 day simple moving average is $19.64. The stock has a market cap of $2.86 billion, a P/E ratio of -2.56, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, analysts expect that Envista Holdings Co. will post 1 EPS for the current fiscal year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.